Maintenance or Discontinuation of Antidepressants in Primary Care
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 12 of the 31 sources its claims cite were checked for support.
Abstract
BACKGROUND Patients with depression who are treated in primary care practices may receive antidepressants for prolonged periods. Data are limited on the effects of maintaining or discontinuing antidepressant therapy in this setting. METHODS We conducted a randomized, double-blind trial involving adults who were being treated in 150 general practices in the United Kingdom. All the patients had a history of at least two depressive episodes or had been taking antidepressants for 2 years or longer and felt well enough to consider stopping antidepressants. Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their current antidepressant therapy (maintenance group) or to taper and discontinue such therapy with the use of matching placebo (discontinuation group). The primary outcome was the first relapse of depression during the 52-week trial period, as evaluated in a time-to-event analysis. Secondary outcomes were depressive and anxiety symptoms, physical and withdrawal symptoms, quality of life, time to stopping an antidepressant or placebo, and global mood ratings. RESULTS A total of 1466 patients underwent screening. Of these patients, 478 were enrolled in the trial (238 in the maintenance group and 240 in the discontinuation group). The average age of the patients was 54 years; 73% were women. Adherence to the trial assignment was 70% in the maintenance group and 52% in the discontinuation group. By 52 we…
Overview
CoChat Summary
TL;DR
In primary care patients who felt well enough to stop long-term antidepressants, tapering to placebo led to a higher risk of depression relapse by 52 weeks than continuing maintenance therapy. Discontinuation was also associated with more depressive, anxiety, and withdrawal symptoms, though serious adverse events were similar between groups.
Key findings
- Relapse of depression by 52 weeks occurred in 92 of 238 patients (39%) in the maintenance group and 135 of 240 (56%) in the discontinuation group (hazard ratio, 2.06; 95% CI, 1.56 to 2.70; P<0.001).
- At 12 weeks, the discontinuation group had worse depressive symptoms (PHQ-9 mean, 4.1 vs. 6.3; difference, 2.2 points; 95% CI, 1.5 to 2.8), anxiety symptoms (GAD-7 mean, 3.1 vs. 5.3; difference, 2.4 points; 95% CI, 1.8 to 3.0), withdrawal symptoms (modified DESS mean, 1.3 vs. 3.1; difference, 1.9 points; 95% CI, 1.5 to 2.3), and mental health–related quality of life (SF-12 mental component mean, 46 vs. 41; difference, −4.9 points; 95% CI, −6.4 to −3.3).
- More patients in the discontinuation group stopped trial medication (48% vs. 30%; hazard ratio, 2.28; 95% CI, 1.68 to 3.08) and returned to an antidepressant prescribed by their primary care doctor (39% vs. 20%).
- Serious adverse events were similar: 9 (4%) in the maintenance group and 8 (3%) in the discontinuation group; there were no deaths or suicide attempts during the trial.
Methods
- Multicenter, randomized, double-blind trial in 150 general practices across four sites in England; adults aged 18 to 74 years were eligible if they had at least two prior depressive episodes or had taken antidepressants for more than 2 years, had been taking standard doses of citalopram, sertraline, fluoxetine, or mirtazapine for at least 9 months, had recovered from their most recent depressive episode, and felt well enough to consider stopping. Current ICD-10 depression was the main exclusion criterion.
- A total of 1466 patients underwent screening; 478 were enrolled and randomly assigned 1:1 to maintain current antidepressant therapy (n=238) or taper and discontinue with matching placebo (n=240), with 52-week follow-up.
- The primary outcome was first relapse of depression during 52 weeks, analyzed in a time-to-event analysis with Cox proportional-hazards modeling adjusted for baseline CIS-R depression score; secondary outcomes included PHQ-9, GAD-7, Toronto Side Effect Scale, modified DESS, SF-12, time to stopping medication, and global mood ratings.
Limitations
- The paper states that it investigated only three SSRIs with similar pharmacologic profiles plus mirtazapine, so findings cannot be generalized to other antidepressant classes; it excluded escitalopram and nonstandard doses; only a small percentage of invited patients participated, which may have introduced bias; findings pertain only to patients who felt ready to discontinue; the relapse measure was adapted and required retrospective assessment over 12 weeks; the population lacked ethnic diversity and was treated entirely in the U.K. health system, limiting generalizability; recall bias was possible; and detailed information about the original prescribing decision or diagnosis was unavailable.
- The paper states that there was no prespecified adjustment for multiple comparisons for secondary outcomes, so no definite conclusions can be drawn from those data.
- Evident from the text: adherence differed between groups (70% maintenance vs. 52% discontinuation), and 39% of the discontinuation group returned to antidepressants by the end of the trial, which may explain the lack of between-group differences at 52 weeks; 10 patients without timing of relapse were excluded from the primary analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 3 Not valid · 2 Not checked · 45 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“We investigated only three selective serotoninreuptake inhibitors that have similar pharmacologic profiles and have similar mechanisms of activity, along with mirtazapine (a noradrenergic and specific serotonergic antidepressant), so we cannot generalize our findings to other classes”
What the sources say
- Disputedcites [23] 23. Lewis G, Duffy L, Ades A, et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled random ised trial. Lancet Psychiatry 2019; 6: 903-14. sourceExperimental — accuracy not yet measured
The Summary (p. 2) says the PANDA trial assigned patients to sertraline or placebo. It did not investigate three SSRIs and mirtazapine, as the citing sentence claims; the Discussion (p. 12) also describes its finding specifically in terms of sertraline. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
- Disputedcites [26] 26. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 2017; 4: 409-18. sourceExperimental — accuracy not yet measured
The cited paper does not present a trial limited to three SSRIs and mirtazapine. Its Introduction discusses several other antidepressant classes, including norepinephrine reuptake inhibitors, bupropion, and SNRIs; the Conclusion describes a broader account of antidepressant mechanisms. No page numbers are available in our copy. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“We determined that the enrollment of 479 patients would provide the trial with 90% power to detect a hazard ratio of 1.92 for the primary outcome in the discontinuation group on the basis of an estimated relapse frequency of 20% in the maintenance group and 35% in the discontinuation group at a two-sided alpha level of 0.05, assuming 20% attrition.”
What the sources say
- Supportedcites [24] 24. Duffy L, Bacon F, Clarke CS, et al. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. Trials 2019; 20: 319. source
The Justification of sample size section gives 90% power at the 5% significance level for relapse rates of 20% in the continuation arm and 35% in the withdrawal arm, and proposes recruiting 479 participants after allowing for 20% attrition. Its hazard ratio of 0.52 compares continuation with withdrawal; reversing that comparison gives approximately 1.92 for withdrawal relative to continuation. (LLM, conf=0.91)
hedgedn = 479- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several systematic reviews of studies have shown a higher rate of relapse among patients who discontinue antidepressant therapy than among those who continue to receive such therapy”
What the sources say
- Not checked — no full text of the sourcecites [6] 6. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 65361. source
- Not checked — no full text of the sourcecites [7] 7. Kaymaz N, van Os J, Loonen AJM, Nolen WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebocontrolled randomized trials. J Clin Psychiatry 2008; 69: 1423-36. source
- Not checked — no full text of the sourcecites [8] 8. Glue P, Donovan MR, Kolluri S, Emir B. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry 2010; 44: 697-705. source
- Supportedcites [9] 9. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and metaanalyses of controlled trials. Int J Neuropsychopharmacol 2015; 19(2): pyv076. source
The Results section, under “Continuation Trials of Antidepressants” (page not provided), reports relapse in 49.4% of patients after discontinuation versus 23.3% of those who continued antidepressants. This directly supports the comparison attributed to this systematic review. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [10] 10. Loonen AJM, Peer PGM, Zwanikken GJ. Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharm Weekbl Sci 1991; 13: 167-75. source
- Not matchedcites [11] 11. Hansen R, Gaynes B, Thieda P, et al.
Its entry has no title and year that we can search by.
- Not checked — no full text of the sourcecites [12] 12. Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol 2009; 24: 401-8. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the categories of serious events were similar in the two groups (Table 3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean score for side effects as assessed on the Toronto scale at 12 weeks was 4.2±2.9 in the maintenance group and 4.6±3.0 in the discontinuation group, for an estimated difference of 0.7 points (95% CI, 0.3 to 1.1).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 55 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 17
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Thus, the differences in relapse rates between individuals with MDD who continued antidepressants that were effective during acute treatment and those who discontinued the antidepressants are still unclear.”
From Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression (2023) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“and relapse rates at 39 weeks of 40 and 69% (29% difference), respectively [2].”
From Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression (2023) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data provide the best evidence for the existence of PAWS, indicating that antidepressant withdrawal symptoms may persist up to at least 39 weeks in some patients.”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lewis et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this study, 39 weeks after patients had started tapering citalopram, fluoxetine, sertraline or mirtazapine, the number of recorded withdrawal symptoms was still significantly increased compared to patients maintained on their antidepressant medication.”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lewis et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, in the design of this RCT, the popular antidepressant drugs paroxetine and venlafaxine were deliberately excluded, because, as written by the authors, both are known to cause marked withdrawal symptoms when treatment is discontinued (Lewis et al., 2021; p. 1258).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Lewis et al., 2021
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Secondary Outcomes
“At 12 weeks, secondary outcomes were generally in the same direction as the primary outcome, except for scores on the SF-12 physical-health component and Toronto Side Effect Scale (Table 2).”
§ The new england journal o f medicine
“| Score on modified Toronto Side Effect Scale | | | | | 12 wk | 4.2±2.9 | 4.6±3.0 | 0.7 (0.3 to 1.1) |”
Citations
Cites
Lewis, G., Pelosi, A. J., Araya, R., & Dunn, G. (1992) · Psychological Medicine · doi:10.1017/s0033291700030415 · Cited by 1,487
Self-citationRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
How do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Different ways to estimate treatment effects in randomised controlled trials
J, T., L, B., T, H., J, R., M, W., & M, H. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.03.008 · Cited by 532
Influences on antidepressant prescribing trends in the UK: 1995–2011
Mars, B., Heron, J., Kessler, D., Davies, N. M., Martin, R. M., Thomas, K. H., & Gunnell, D. (2017) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1306-4 · Cited by 419
Self-citationFive-Year Outcome for Maintenance Therapies in Recurrent Depression
Kupfer, D. J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100013002 · Cited by 370
Wiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., Garland, A., Hollinghurst, S., Jerrom, B., Kessler, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61552-9 · Cited by 340
Self-citationMoore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287
Self-citationKendrick, T., Dowrick, C., McBride, A., Howe, A., Clarke, P., Maisey, S., Moore, M., & Smith, P. W. (2009) · BMJ · doi:10.1136/bmj.b750 · Cited by 231
Self-citation
Cited by
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
“Ongoing prescription of antidepressants should be routinely re-evaluated to prevent relapse, which is more frequent after discontinuation of antidepressants 209 , to ensure the medication is still effective, and that the benefit of treatment outweighs potential adverse effects.”
Novel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., et al. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241245384 · Cited by 369
British Society of Gastroenterology guidelines on the management of functional dyspepsia
Black, C. J., Paine, P. A., Agrawal, A., Aziz, I., Eugenicos, M. P., Houghton, L. A., Hungin, P., Overshott, R., Vasant, D. H., Rudd, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327737 · Cited by 193
Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents
Strawn, J. R., Mills, J. A., Poweleit, E. A., Ramsey, L. B., & Croarkin, P. E. (2023) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2767 · Cited by 185
Promoting good mental health over the menopause transition
Brown, L., Hunter, M. S., Chen, R., Crandall, C. J., Gordon, J. L., Mishra, G. D., Rother, V., Joffe, H., & Hickey, M. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02801-5 · Cited by 166
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use
Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179910 · Cited by 67
“Antidepressant discontinuation is associated with relapse and withdrawal phenomena that may put patients at risk of serious harm (Gemma et al., 2021; Hengartner et al., 2020).”
BackgroundGastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 64
“Finally, the risk/benefits balance of long-term treatment or ‘maintenance’ antidepressant treatment should be reassessed [47, 55].”
BackgroundPolypharmacy and Deprescribing in Older Adults
Thompson, W., & McDonald, E. G. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-070822-101947 · Cited by 88
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
“A landmark study pointed in the same direction in the context of primary care [16].”
BackgroundTargeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Self-citationDigital health technologies and major depressive disorder
McIntyre, R. S., Greenleaf, W., Bulaj, G., Taylor, S. T., Mitsi, G., Saliu, D., Czysz, A., Silvesti, G., Garcia, M., & Jain, R. (2023) · CNS Spectrums · doi:10.1017/s1092852923002225 · Cited by 38
“43,44 Both the American Psychiatric Association and the American Psychological Association practice guidelines recommend that HCPs consider appropriate treatments (including both pharmacologic and nonpharmacologic therapy options) for preventing relapse in patients with depression who have achieved…”
BackgroundFava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000520251 · Cited by 46
Horowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000080 · Cited by 33
Liang, X., Tang, J., Qi, Y., Luo, Y., Yang, C., Dou, X., Jiang, L. H., Xiao, Q., Zhang, L., Chao, F., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114103 · Cited by 36
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
Read, J., Moncrieff, J., & Horowitz, M. A. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.013 · Cited by 30
Jayasooriya, N., Blackwell, J., Saxena, S., Bottle, A., Petersen, I., Creese, H., Hotopf, M., Pollok, R. C. G., & POP‐IBD study group (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16820 · Cited by 27
Hauff, J., Rottenkolber, M., Oehler, P., Fischer, S., Gensichen, J. S., Drey, M., Alexander, G. C., Guthrie, B., & Dreischulte, T. (2023) · Age and Ageing · doi:10.1093/ageing/afad079 · Cited by 25
Kishi, T., Sakuma, K., Hatano, M., Okuya, M., Matsuda, Y., Kato, M., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01920-0 · Cited by 26
“A subsequent DBRPCT found relapse rates for an antidepressant maintenance group and a discontinuation group at 26 weeks of 32 and 56% (24% difference), respectively; and relapse rates at 39 weeks of 40 and 69% (29% difference), respectively [2].”
BackgroundStimpfl, J. N., Walkup, J. T., Robb, A. S., Alford, A. E., Stahl, S. M., McCracken, J. T., Stancil, S. L., Ramsey, L. B., Emslie, G. J., & Strawn, J. R. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0099 · Cited by 32
“In the ANTLER study, adults taking mirtazapine 30mg took 15 mg daily for 1 month and then 15 mg every other day (Lewis et al., 2021).”
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Duffy, L., Clarke, C. S., Lewis, G., Marston, L., Freemantle, N., Gilbody, S. M., Hunter, R. M., Kendrick, T., Kessler, D. S., King, M., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25690 · Cited by 27
“3 to 5 years 81/238 (34) 79/239 (33) 6 to 10 years 48/238 (20) 48/239 (20) ≥ 11 years 41/238 (17) 41/239 (17) continued DOI: 10.”
Self-citationKendrick, T., Stuart, B. L., Bowers, H. M., Sadeghi, M. H., Hl, P., Dowrick, C. F., Moore, M. V., Gabbay, M., Leydon, G., Yao, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18383 · Cited by 27
Self-citationSaunders, R., Cohen, Z. D., Ambler, G., DeRubeis, R. J., Wiles, N., Kessler, D., Gilbody, S., Hollon, S. D., Kendrick, T., Watkins, E., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121295 · Cited by 21
“Although pharmacogenetics may hold promise for personalizing antidepressant treatments [15,16], it is becoming increasingly common that antidepressants are prescribed indefinitely for all patients with a history of previous relapses, to mitigate the risks of chronic illness and relapse [11,12,17,18].”
BackgroundSelf-citationHorowitz, M. A., Buckman, J. E. J., Saunders, R., Aguirre, E., Davies, J., & Moncrieff, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116497 · Cited by 25
“In a double-blind RCT of patients who had been taking antidepressants for > 2 years, withdrawal symptoms were increased for, on average, 9 months after stopping (Lewis et al., 2021), somewhat longer than the equivalent group in our study of whom 30 % reported symptoms of longer than 3 months.”
Antidepressants and the serotonin hypothesis of depression
Kendrick, T., & Collinson, S. (2022) · BMJ · doi:10.1136/bmj.o1993 · Cited by 22
Self-citationPharmacomicrobiomics of Antidepressants in Depression: A Systematic Review
Brown, L. C., Bobo, W. V., Gall, C. A., Müller, D. J., & Bousman, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071086 · Cited by 27
“More importantly, in a recently-published randomized trial, over half (56%) of patients with recurrent MDD who stopped antidepressants relapsed during 52 weeks of follow-up, as compared to a relapse rate of 39% for those who continued their antidepressant [62].”
BackgroundMoncrieff, J., Read, J., & Horowitz, M. A. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100765 · Cited by 20
“The total of 15 was chosen as a balance between convenience for clinicians and comprehensiveness, reflecting the use of 15 items for an abbreviated version of the DESS used in a large-scale RCT of antidepressant discontinuation (Lewis et al., 2021)).”
Crescenzo, F. D., Giorgi, R. D., Garriga, C., Liu, Q., Fazel, S., Efthimiou, O., Hippisley‐Cox, J., & Cipriani, A. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.194 · Cited by 26
“In the routine clinical practice world, high discontinuation rates of antidepressants can have serious consequences for people, as they are associated with a high risk of relapse.”
The PrLGlu→avBNSTGABA circuit rapidly modulates depression-like behaviors in male mice
Chen, J.-Y., Wu, K., Guo, M., Song, W., Huang, S.-T., & Zhang, Y.-M. (2023) · iScience · doi:10.1016/j.isci.2023.107878 · Cited by 19
“In spite of a growing body of work elucidating the mechanisms underlying depression, much of the underlying neurobiology is still uncertain and, as a result, the development of new clinical therapies has been extremely slow with poor outcomes.(3) For effective development of rapid-acting antidepressant therapies, it i…”
BackgroundNash, C. (2022) · Challenges · doi:10.3390/challe13020028 · Cited by 23
Amygdala Reactivity, Antidepressant Discontinuation, and Relapse
Erdmann, T., Berwian, I. M., Stephan, K. E., Seifritz, E., Walter, H., & Huys, Q. J. M. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.2136 · Cited by 18
Antidepressants overuse in primary care: Prescription trends between 2010 and 2019 in Catalonia
Anmella, G., Sanabra, M., Primé‐Tous, M., Segú, X., Solanes, A., Ruíz, V., Morilla, I., Fontanet, A. A., Sant, E., Murgui, S., et al. (2022) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2022.12.001 · Cited by 21
Guo, H., Ren, Y., Huang, B., Wang, J., Yang, X., & Wang, Y. (2022) · Genetics Research · doi:10.1155/2022/1097982 · Cited by 22
“(erefore, it is essential to start new treatment to enhance response rate and reduce recurrence rate [7].”
Background(2024) · doi:10.1016/j.psychres.2024.115926 · Cited by 15
Mahmood, R., Wallace, V., Wiles, N., Kessler, D. S., Button, K. S., & Fairchild, G. F. (2024) · Health Expectations · doi:10.1111/hex.13966 · Cited by 12
Self-citationErwartungseffekte beim Absetzen von Antidepressiva: Implikationen für die Praxis
Nestoriuc, Y. (2022) · Psychotherapeut · doi:10.1007/s00278-022-00587-w · Cited by 10
Nicola, M. D., Dell’Osso, B. M., Peduto, I., Cipelli, R., Pugliese, A. C., Signorelli, M. S., Ventriglio, A., & Martinotti, G. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411092813 · Cited by 17
“In patients who felt well enough to discontinue treatment, those discontinuing their antidepressants had a higher risk of relapse of depression at one year compared to patients who continued antidepressant treatment [53].”
Antidepressant Discontinuation Syndrome
Kim, S. H., Kim, Y. S., & Kang, U. G. (2024) · 신경정신의학 · doi:10.4306/jknpa.2024.63.2.104 · Cited by 12
Zhang, S., Xu, Y., & Xia, Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.002 · Cited by 15
Onwubu, S. C., Sibiya, M. N., & Makgobole, M. U. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176683 · Cited by 17
“This can have serious consequences for patients with chronic mental health conditions, as interrupted or inconsistent medication use may result in symptom exacerbation and a higher risk of relapse [30].”
BackgroundXiao, C., Zhou, J. L., Li, A., Zhang, L., Zhu, X., Zhou, J., Hu, Y., Zheng, Y., Liu, J., Deng, Q., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28817 · Cited by 14
Alnsasra, H., Khalil, F. M., Perue, R. K., & Azab, A. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411270 · Cited by 17
“Nevertheless, despite the evidence attesting to the efficacy of these medications [2,39,41], a large percentage of patients do not respond to treatment, and/or suffer a plethora of unwanted side effects, resulting in low adherence to treatment and relapse of symptoms [2,40,43–47].”
BackgroundGiorgi, R. D., Crescenzo, F. D., Cowen, P. J., Harmer, C. J., & Cipriani, A. (2023) · BMC Medicine · doi:10.1186/s12916-023-03138-5 · Cited by 11
“Antidepressant adherence is an important concern: a recent trial in primary care patients has linked antidepressant treatment discontinuation to a higher risk of depressive relapse ( N 478, hazard ratio 2.06, 95% CI 1.56 to 2.70) within 1 year [38].”
BackgroundInfluentialMeißner, C., Warren, C. V., Fadai, T., Müller, A., Zapf, A., Lezius, S., Ozga, A., Falkenberg, I., Kircher, T. T. J., & Nestoriuc, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04941-3 · Cited by 11
“Nevertheless, some patients appear to be at increased risk for recurrence following discontinuation [7, 40].”
BackgroundYamazaki, R., Matsuda, Y., Oba, M. S., Oi, H., & Kito, S. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04944-0 · Cited by 11
Khalifeh, A. H., Alhalaiqa, F., Hamaideh, S. H., Horne, R., & Hamdan‐Mansour, A. M. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13113 · Cited by 18
Interventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2024) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 15
“…[30,31,33–36, 38], depression ( Tapering was assisted by cognitive behaviour therapy (CBT) in five studies [30–32,36 ,37 ] All studies but one [67] appeared to have stopped the drug at the lowest standard manufactured dose – corresponding to high receptor occupancy – as there was no mention…”
InfluentialJeffery, A., Bhanu, C., Walters, K. R., Wong, I. C. K., Osborn, D., & Hayes, J. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2022.160 · Cited by 16
Rigdon, G. C., Prescott, Y., Hall, J. P., Abernathy, K., Raskin, J., & Wargin, W. A. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1488 · Cited by 12
Deprescribing antidepressants for depression – what is the evidence for and against?
Looi, J. C., Allison, S. C., Bastiampillai, T. J., Kisely, S. R., Maguire, P. A., Woon, L. S., Anderson, K., & Malhi, G. S. (2024) · Australasian Psychiatry · doi:10.1177/10398562241282377 · Cited by 8
Leeuwen, E. V., Maund, E., Woods, C. J., Bowers, H. M., Christiaens, T., & Kendrick, T. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.060 · Cited by 14
Self-citationZhao, Y., Zhang, Y., Yang, L., Zhang, K., & Li, S. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241231116 · Cited by 15
Duffy, L., Lewis, G., Marston, L., Kendrick, T., Kessler, D., Moore, M., Wiles, N., & Lewis, G. (2024) · Psychological Medicine · doi:10.1017/s0033291723002659 · Cited by 8
“Time to relapse of depression was the primary outcome, assessed by the retrospective CIS-R (rCIS-R) (Lewis et al., 2021), which asked about the previous 12 weeks, at the 12, 26, 39 and 52 week follow-ups.”
InfluentialSelf-citationWhat Should Clinicians Know About Palliative Psychopharmacology?
(2023) · AMA Journal of Ethics · doi:10.1001/amajethics.2023.710 · Cited by 7
Clarke, C. S., Duffy, L., Lewis, G., Freemantle, N., Gilbody, S. M., Kendrick, T., Kessler, D. S., King, M., Lanham, P., Mangin, D. A., et al. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00693-x · Cited by 7
“The ANTLER study [9, 10] was a double-blind randomised controlled trial evaluating tapering of participants’ antidepressant medications down to zero dose (discontinuation arm) compared with antidepressant maintenance therapy continuing with participants’ current prescriptions (maintenance arm).”
BackgroundMethodInfluentialSelf-citationRennwald, A., & Hengartner, M. P. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602500023x · Cited by 8
Fi, B., Sumin, A. N., Garganeeva, N. P., Ларева, Н. В., Петрова, М. М., Петрунько, О. В., Попонина, Т. М., Repin, A. N., & Собенников, В. С. (2024) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2024-13-3s-222-253 · Cited by 9
Mir, F. A., Morgan, L., & Houghton, E. (2021) · BMJ · doi:10.1136/bmj.n2539 · Cited by 11
Hidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse
Horowitz, M. A., & Davies, J. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000542437 · Cited by 7
“This approach was questionable given that high rates of withdrawal effects (which persisted for 9 months after drug cessation) were registered in this study [31, 32], casting serious doubt on the ANTLER ’ s conclusion that antidepressants reduce relapse risk.”
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 13
Maes, M. H. J., Almulla, A. F., Stoyanov, D., & Zhang, Y. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2608029 · Cited by 10
“Meta-analyses indicate a substantial reduction in relapse rates with SSRIs and tricyclic antidepressants (TCAs) compared to placebo, and maintenance therapy with these drugs may further diminish relapse occurrences [127,128].”
Concomitant use of antidepressants and classic psychedelics: A scoping review
Tap, S. C., Thomas, K. L. H., Páleníček, T., Stenbæk, D. S., Oliveira-Maia, A. J., van Dalfsen, J. H., & Schoevers, R. A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368360 · Cited by 16
“…and increased suicidal ideation that would then occur prior to a potentially challenging psyche-delic experience, either through rebound effects, AD discontinuation syndrome, or by interrupting a (partially) effective treatment (Davies and Read, 2019; Kato et al., 2021; Lewis et al., 2021).”
Lam, R. W., Rnic, K., Nunez, J.-J., Ho, K., LeMoult, J., Nunes, A., Chakrabarty, T., Foster, J. A., Frey, B. N., Harkness, K. L., et al. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251337603 · Cited by 6
Antidepressant prescribing in Australian primary care: time to reevaluate
Wallis, K. A., King, A., & Moncrieff, J. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.52645 · Cited by 6
“19 Yet, arguably these trials stop antidepressants too precipitously and misinterpret physiological withdrawal symptoms as relapse.”
Coe, A., Gunn, J. M., Allnutt, Z., & Kaylor‐Hughes, C. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078179 · Cited by 6
“17 18 Trials of antidepressant tapering versus placebo have had limited success with high rates of relapse among the intervention group (eg, see Eveleigh et al 19 and Lewis et al 20 ).”
BackgroundSakhvidi, M. N., salami, Z., Mosadegh, M., Bidaki, R., Fallahzadeh, H., Salehabadi, R., & Arjmandi, M. (2023) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174231210567 · Cited by 7
“7 These complaints may not solely respond to antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and may ultimately lead to increased drug dosage, which is accompanied by increased risk for potential side effects, or combination therapy, which may increase the likelihood of…”
Shapiro, B. B., Kramer, E. N., Khoury, D., & Preda, A. (2023) · Pharmacopsychiatry · doi:10.1055/a-2078-4593 · Cited by 6
“There have been more recent efforts to refine the DESS scale to fewer checklist items, including a 23-item version [8] and a 15-item version [9], though with concern that reducing the number of checklist items may reduce the scale’s sensitivity for detecting antidepressant withdrawal [10].”
BackgroundRethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
“Guidelines also offer little evidence as a basis for deciding between transitioning from continuation treatment to maintenance treatment to prevent future episodes versus tapering off medication after the continuation treatment phase [16].”
BackgroundAnmella, G., Meehan, A., Ashton, M. M., Mohebbi, M., Fico, G., Ng, C. H., Maes, M. H. J., Berk, L., Prisco, M. D., Singh, A., et al. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1098 · Cited by 7
“The clinical course of MDD is highly variable, but over their lifetime, around 80% of people affected by this illness manifest recurrent depressive episodes [3], especially if antidepressant treatment is discontinued [4].”
BackgroundMalhi, G. S., Bell, E., Bassett, D. L., Boyce, P. M., Hopwood, M., Mulder, R., & Porter, R. (2023) · Bipolar Disorders · doi:10.1111/bdi.13350 · Cited by 5
Antidepressant Tapering Is Not Routine But Could Be
Phelps, J. R., Nguyen, J., & Pipitone, O. (2023) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2022.220239r1 · Cited by 5
“” 12 In that trial ’ s taper process, doses were cut in half for a month; then that lowered dose was taken every other day for a month, then stopped.”
BackgroundSeifert, J., Bleich, S., & Seifert, R. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_22 · Cited by 6
Influence of antidepressant use on periodontal status: a systematic review and meta-analysis
de Oliveira, I. C. V., Alencar-Júnior, H. D. S., Campos, H. R. S. S., Rodrigues, V. P., & Branco‐de‐Almeida, L. S. (2025) · Clinical Oral Investigations · doi:10.1007/s00784-025-06317-1 · Cited by 4
“Antidepressants are commonly prescribed for depression, anxiety, other psychiatric disorders, chronic pain, and eating disorders [1, 2], with prescriptions significantly increasing over the past two decades [3, 4].”
Fortier, L. M., Moyal, A. J., Dave, U., Burkhart, R. J., Adelstein, J. M., Strony, J. T., Sinkler, M. A., & Napora, J. K. (2025) · Injury · doi:10.1016/j.injury.2025.112236 · Cited by 5
Berwian, I. M., Tröndle, M., de Miquel, C., Ziogas, A., Stefanics, G., Walter, H., Stephan, K. E., & Huys, Q. J. M. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.05.001 · Cited by 10
“The choice of whether to discontinue an antidepressant medication plays an important role in this setting because relapses frequently follow discontinuation: around one third of those who discontinue antidepressant medication suffer a relapse within months of discontinuation (6,7,8,9,10).”
Psychopharmacological treatment in patients planned for hip or knee replacement
Kornvig, S., Kehlet, H., Jørgensen, C. C., Fink‐Jensen, A., Videbech, P., Lindberg‐Larsen, M., Gromov, K., Rasmussen, M. B., Bieder, M. J., & Varnum, C. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14017 · Cited by 5
“17,18 The discontinuation syndrome is characterized by flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances and hyperarousal and occurs in about 20% after abrupt discontinuation.”
BackgroundDuffy, L., Marston, L., Lewis, G., & Lewis, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280997 · Cited by 4
“Our study was a part of the ANTidepressants to prevent reLapse in dEpRession (ANTLER) study [16].”
BackgroundMethodSelf-citationDependence on newer generation antidepressants
Vaaler, A. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0339 · Cited by 4
Maintenance or Discontinuation of Antidepressants in Primary Care
Liang, C.-S., Tseng, P.-T., & Chen, M.-H. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2117168 · Cited by 6
Self-citationAbukmail, E., Pradeep, N. K., Ahmed, S., & Albarqouni, L. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03016 · Cited by 4
Leeuwen, E. V., Mehuys, E., Johnson, C. F. A., Keyzer, A.-S. D., Boussery, K., & Christiaens, T. C. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251333977 · Cited by 6
“45,46 Moreover, evidence from a Cochrane systematic review suggests that with psychotherapeutic support, between 40% and 75% of individuals with recurrent depression can successfully stop taking their antidepressants.”
Effects of antidepressants on body weight in patients treated in a naturalistic setting in Oman
Al-Jahwari, L., Qutishat, M., Al-Maqbali, M., Alrisi, K. A., AlBreiki, M., Albalushi, M., & Al‐Huseini, S. (2025) · Middle East Current Psychiatry · doi:10.1186/s43045-025-00496-z · Cited by 4
Chokroverty, L. (2024) · Pediatrics in Review · doi:10.1542/pir.2024-006479 · Cited by 3
Alsabhan, J. F., Alanazi, A., Alhajaji, R., Elbashir, M., Alzahrani, F., Alhajaji, F., Almehmadi, M., Alqorashi, S., Fairaq, B. A., & Alhazmi, F. (2024) · Cureus · doi:10.7759/cureus.65562 · Cited by 5
“These programs prioritize the early detection and treatment of prevalent mental health diseases such as MDD, generalized anxiety disorder, and panic disorder [10].”
InfluentialStephenson, J. J., Touya, M., Chrones, L., Pandya, S. A., Teng, C., & Clayton, A. H. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100750 · Cited by 4
Half of people who stopped long term antidepressants relapsed within a year, study finds
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n2403 · Cited by 3
Do withdrawal symptoms predict depression relapse after antidepressant cessation?
Volkmann, C., Abulikemu, S., Berwian, I. M., Huys, Q. J. M., & Walter, H. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02005-z · Cited by 5
Burgess, J. L., Ismail, K., Raymont, V., Emsley, R., Beckley‐Hoelscher, N., Wall, J., Dilley, M. D., Ahmed, A. I., Barrett, B. M., Longson, D., et al. (2025) · Trials · doi:10.1186/s13063-025-09027-x · Cited by 3
Pan, Z., Zhang, H., Li, B., Huang, Z., Hu, Y., Chen, J., Lam, R. W. M., & Fang, Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119460 · Cited by 3
Abu-Ashour, W., Delaney, S., Farrell, A., Gamble, J., Hawboldt, J., & Sale, J. E. M. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251322401 · Cited by 5
Dewar-Haggart, R., Müller, I., Bishop, F. L., Geraghty, A. W. A., Stuart, B. L., & Kendrick, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0299676 · Cited by 3
“Over the past two decades, antidepressant prescribing rates have risen considerably, nearly doubling between 2008 and 2018 [1,2].”
Self-citationSeifert, J., Bleich, S., & Seifert, R. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_22 · Cited by 3
Horowitz, M. A., & Taylor, D. M. (2024) · Australasian Psychiatry · doi:10.1177/10398562241308437 · Cited by 2
“29,30 Therefore this study, like other discontinuation studies, does not present robust evidence that antidepressants prevent relapse because of confounding by withdrawal effects.”
Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Sekine, D., Aoki, K., Shiomi, Y., & Higuchi, T. (2024) · CNS Drugs · doi:10.1007/s40263-024-01124-w · Cited by 5
“…controlled trial of adults with MDD treated across 150 general practices in the UK, relapse was significantly higher ( p 0.001) in patients who discontinued ADT after 2 years compared with those who continued ADT for an additional year [9], highlighting the need for long-term maintenance therapy.”
InfluentialDiscontinuation symptoms of antidepressants
Lewis, G., & Lewis, G. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00174-3 · Cited by 2
Self-citationBerwian, I. M., Tröndle, M., Miquel, C. D., Ziogas, A., Stefanics, G., Walter, H., Stephan, K. E., & Huys, Q. J. M. (2023) · doi:10.1101/2023.07.05.547831 · Cited by 2
Metadata
- Authors
- Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., Hunt, A., Pervin, J., & Lewis, G.
- Affiliations
- University of Bristol (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-30
- Volume
- 385
- Issue
- 14
- Pages
- 1257-1267
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3204219363
- Cited by
- 192
- References
- 25
- Citations by year
- 2026: 33 · 2025: 42 · 2024: 44 · 2023: 35 · 2022: 27 · 2021: 10
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Liverpool John Moores University (acceptedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- Health Technology Assessment Programme (13/115/48)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- antidepressant discontinuation, antidepressant tapering, depression relapse, long-term antidepressant use, citalopram, fluoxetine, sertraline, mirtazapine, withdrawal symptoms, primary care depression, quality of life
- MeSH terms
- Adult, Aged, Antidepressive Agents, Anxiety Disorders, Depressive Disorder, Double-Blind Method, Female, Follow-Up Studies, United Kingdom, Humans, Male, Middle Aged, Primary Health Care, Surveys and Questionnaires, Recurrence, Citalopram, Selective Serotonin Reuptake Inhibitors, Withholding Treatment, Kaplan-Meier Estimate, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.